Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis
|
摘要
Hepatocellular carcinoma(HCC) is the 5 th most frequently diagnosed cancer in the world, according to the World Health Organization. The incidence of HCC is between 3/100000 and 78.1/100000, with a high incidence reported in areas with viral hepatitis B and hepatitis C, thus affecting Asia and Africa predominantly.Several international clinical guidelines address HCC diagnosis and are structured according to the geographical area involved. All of these clinical guidelines, however, share a foundation of diagnosis by ultrasound surveillance and contrast imaging techniques, particularly computed tomography, magnetic resonance imaging, and sometimes contrast-enhanced ultrasound. The primary objective of this review was to systematically summarize the recent published studies on the clinical utility of serum biomarkers in the early diagnosis of HCC and for the prognosis of this disease.
Hepatocellular carcinoma(HCC) is the 5 th most frequently diagnosed cancer in the world, according to the World Health Organization. The incidence of HCC is between 3/100000 and 78.1/100000, with a high incidence reported in areas with viral hepatitis B and hepatitis C, thus affecting Asia and Africa predominantly.Several international clinical guidelines address HCC diagnosis and are structured according to the geographical area involved. All of these clinical guidelines, however, share a foundation of diagnosis by ultrasound surveillance and contrast imaging techniques, particularly computed tomography, magnetic resonance imaging, and sometimes contrast-enhanced ultrasound. The primary objective of this review was to systematically summarize the recent published studies on the clinical utility of serum biomarkers in the early diagnosis of HCC and for the prognosis of this disease.
Hepatocellular carcinoma(HCC) is the 5 th most frequently diagnosed cancer in the world, according to the World Health Organization. The incidence of HCC is between 3/100000 and 78.1/100000, with a high incidence reported in areas with viral hepatitis B and hepatitis C, thus affecting Asia and Africa predominantly.Several international clinical guidelines address HCC diagnosis and are structured according to the geographical area involved. All of these clinical guidelines, however, share a foundation of diagnosis by ultrasound surveillance and contrast imaging techniques, particularly computed tomography, magnetic resonance imaging, and sometimes contrast-enhanced ultrasound. The primary objective of this review was to systematically summarize the recent published studies on the clinical utility of serum biomarkers in the early diagnosis of HCC and for the prognosis of this disease.
引文
1 Mak LY,Cruz-Ramón V,Chinchilla-López P,Torres HA,LoConte NK,Rice JP,Foxhall LE,Sturgis EM,Merrill JK,Bailey HH,Méndez-Sánchez N,Yuen MF,Hwang JP.Global Epidemiology,Prevention,and Management of Hepatocellular Carcinoma.Am Soc Clin Oncol Educ Book 2018;38:262-279[PMID:30231359 DOI:10.1200/EDBK_200939]
2 Geneva:World Health Organization.Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection.[PMID:26225396]
3 Geneva:World Health Organization.WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection:Update Version.[PMID:27227200]
4 Burak KW,Sherman M.Hepatocellular carcinoma:Consensus,controversies and future directions.Areport from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.Can JGastroenterol Hepatol 2015;29:178-184[PMID:25965437]
5 Heimbach JK,Kulik LM,Finn RS,Sirlin CB,Abecassis MM,Roberts LR,Zhu AX,Murad MH,Marrero JA.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology 2018;67:358-380[PMID:28130846 DOI:10.1002/hep.29086]
6 Marrero JA,Ahn J,Rajender Reddy K;Americal College of Gastroenterology.ACG clinical guideline:the diagnosis and management of focal liver lesions.Am J Gastroenterol 2014;109:1328-1347;quiz 1348[PMID:25135008 DOI:10.1038/ajg.2014.213]
7 Benson AB,D'Angelica MI,Abbott DE,Abrams TA,Alberts SR,Saenz DA,Are C,Brown DB,Chang DT,Covey AM,Hawkins W,Iyer R,Jacob R,Karachristos A,Kelley RK,Kim R,Palta M,Park JO,Sahai V,Schefter T,Schmidt C,Sicklick JK,Singh G,Sohal D,Stein S,Tian GG,Vauthey JN,Venook AP,Zhu AX,Hoffmann KG,Darlow S.NCCN Guidelines Insights:Hepatobiliary Cancers,Version 1.2017.J Natl Compr Canc Netw 2017;15:563-573[PMID:28476736]
8 Optimal cancer care pathway for people with hepatocellular carcinoma.Available from:www.cancer.org.au/ocp
9 European Association for the Study of the Liver.European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma.J Hepatol 2018;69:182-236[PMID:29628281 DOI:10.1016/j.jhep.2018.03.019]
10 Vogel A,Cervantes A,Chau I,Daniele B,Llovet J,Meyer T,Nault JC,Neumann U,Ricke J,Sangro B,Schirmacher P,Verslype C,Zech CJ,Arnold D,Martinelli E;ESMO Guidelines Committee.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol 2018;29:iv238-iv255[PMID:30285213 DOI:10.1093/annonc/mdy308]
11 Kokudo N,Hasegawa K,Akahane M,Igaki H,Izumi N,Ichida T,Uemoto S,Kaneko S,Kawasaki S,Ku Y,Kudo M,Kubo S,Takayama T,Tateishi R,Fukuda T,Matsui O,Matsuyama Y,Murakami T,Arii S,Okazaki M,Makuuchi M.Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma:The Japan Society of Hepatology 2013 update(3rd JSH-HCC Guidelines).Hepatol Res 2015;45[PMID:25625806 DOI:10.1111/hepr.12464]
12 Omata M,Cheng AL,Kokudo N,Kudo M,Lee JM,Jia J,Tateishi R,Han KH,Chawla YK,Shiina S,Jafri W,Payawal DA,Ohki T,Ogasawara S,Chen PJ,Lesmana CRA,Lesmana LA,Gani RA,Obi S,Dokmeci AK,Sarin SK.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update.Hepatol Int 2017;11:317-370[PMID:28620797 DOI:10.1007/s12072-017-9799-9]
13 Claudon M,Dietrich CF,Choi BI,Cosgrove DO,Kudo M,Nols?e CP,Piscaglia F,Wilson SR,Barr RG,Chammas MC,Chaubal NG,Chen MH,Clevert DA,Correas JM,Ding H,Forsberg F,Fowlkes JB,Gibson RN,Goldberg BB,Lassau N,Leen EL,Mattrey RF,Moriyasu F,Solbiati L,Weskott HP,Xu HX.Guidelines and good clinical practice recommendations for contrast enhanced ultrasound(CEUS)in the liver--update 2012:a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB,AIUM,ASUM,FLAUS and ICUS.Ultraschall Med 2013;34:11-29[PMID:23129518 DOI:10.1055/s-0032-1325499]
14 Wang K,Bai Y,Chen S,Huang J,Yuan J,Chen W,Yao P,Miao X,Wang Y,Liang Y,Zhang X,He M,Yang H,Guo H,Wei S.Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.Cancer Med 2018;7:2691-2698[PMID:29696820 DOI:10.1002/cam4.1481]
15 Tayob N,Richardson P,White DL,Yu X,Davila JA,Kanwal F,Feng Z,El-Serag HB.Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.BMC Med Res Methodol 2018;18:1[PMID:29301497 DOI:10.1186/s12874-017-0458-6]
16 Wang M,Devarajan K,Singal AG,Marrero JA,Dai J,Feng Z,Rinaudo JA,Srivastava S,Evans A,Hann HW,Lai Y,Yang H,Block TM,Mehta A.The Doylestown Algorithm:A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.Cancer Prev Res(Phila)2016;9:172-179[PMID:26712941 DOI:10.1158/1940-6207.CAPR-15-0186]
17 Yu R,Ding S,Tan W,Tan S,Tan Z,Xiang S,Zhou Y,Mao Q,Deng G.Performance of Protein Induced by Vitamin K Absence or Antagonist-II(PIVKA-II)for Hepatocellular Carcinoma Screening in Chinese Population.Hepat Mon 2015;15:e28806[PMID:26300931 DOI:10.5812/hepatmon.28806v2]
18 Chen H,Zhang Y,Li S,Li N,Chen Y,Zhang B,Qu C,Ding H,Huang J,Dai M.Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma.Cancer Manag Res 2018;10:1947-1958[PMID:30022853 DOI:10.2147/CMAR.S167036]
19 Fu J,Li Y,Li Z,Li N.Clinical utility of decarboxylation prothrombin combined withα-fetoprotein for diagnosing primary hepatocellular carcinoma.Biosci Rep 2018;38[PMID:29717027 DOI:10.1042/BSR20180044]
20 Qin QF,Weng J,Xu GX,Chen CM,Jia CK.Combination of serum tumor markers dickkopf-1,DCP and AFP for the diagnosis of primary hepatocellular carcinoma.Asian Pac J Trop Med 2017;10:409-413[PMID:28552111 DOI:10.1016/j.apjtm.2017.03.016]
21 Chen J,Wu G,Li Y.Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma:A Meta-Analysis.Dis Markers 2018;2018:8906023[PMID:30402170 DOI:10.1155/2018/8906023]
22 Beale G,Chattopadhyay D,Gray J,Stewart S,Hudson M,Day C,Trerotoli P,Giannelli G,Manas D,Reeves H.AFP,PIVKAII,GP3,SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.BMC Cancer 2008;8:200[PMID:18638391DOI:10.1186/1471-2407-8-200]
23 Yu Y,Song J,Zhang R,Liu Z,Li Q,Shi Y,Chen Y,Chen J.Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma.Oncotarget 2017;8:79722-79730[PMID:29108352 DOI:10.18632/oncotarget.19178]
24 Li B,Li B,Guo T,Sun Z,Li X,Li X,Chen L,Zhao J,Mao Y.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels ofα-fetoprotein,α-fetoprotein-L3,des-γ-carboxy prothrombin,and Golgi protein 73.Oncotarget 2017;8:80521-80530[PMID:29113322 DOI:10.18632/oncotarget.19298]
25 Gao J,Song P.Combination of triple biomarkers AFP,AFP-L3,and PIVAKII for early detection of hepatocellular carcinoma in China:Expectation.Drug Discov Ther 2017;11:168-169[PMID:28757516DOI:10.5582/ddt.2017.01036]
26 Caviglia GP,Abate ML,Petrini E,Gaia S,Rizzetto M,Smedile A.Highly sensitive alpha-fetoprotein,Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.Hepatol Res 2016;46:E130-E135[PMID:26082262 DOI:10.1111/hepr.12544]
27 Best J,Bilgi H,Heider D,Schotten C,Manka P,Bedreli S,Gorray M,Ertle J,van Grunsven LA,Dechêne A.The GALAD scoring algorithm based on AFP,AFP-L3,and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.Z Gastroenterol 2016;54:1296-1305[PMID:27936479DOI:10.1055/S-0042-119529]
28 Berhane S,Toyoda H,Tada T,Kumada T,Kagebayashi C,Satomura S,Schweitzer N,Vogel A,Manns MP,Benckert J,Berg T,Ebker M,Best J,Dechêne A,Gerken G,Schlaak JF,Weinmann A,W?rns MA,Galle P,Yeo W,Mo F,Chan SL,Reeves H,Cox T,Johnson P.Role of the GALAD and BALAD-2Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.Clin Gastroenterol Hepatol 2016;14:875-886.e6[PMID:26775025 DOI:10.1016/j.cgh.2015.12.042]
29 Oeda S,Iwane S,Takasaki M,Furukawa NE,Otsuka T,Eguchi Y,Anzai K.Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival.Intern Med 2016;55:2749-2758[PMID:27725532 DOI:10.2169/internalmedicine.55.6730]
30 Wongjarupong N,Negron-Ocasio GM,Chaiteerakij R,Addissie BD,Mohamed EA,Mara KC,Harmsen WS,Theobald JP,Peters BE,Balsanek JG,Ward MM,Giama NH,Venkatesh SK,Harnois DM,Charlton MR,Yamada H,Algeciras-Schimnich A,Snyder MR,Therneau TM,Roberts LR.Model combining pretransplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.World J Gastroenterol 2018;24:1321-1331[PMID:29599607 DOI:10.3748/wjg.v24.i12.1321]
31 Li B,Li B,Guo T,Sun Z,Li X,Li X,Wang H,Chen W,Chen P,Mao Y.The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma.Biomed Res Int 2017;2017:5358615[PMID:28540298 DOI:10.1155/2017/5358615]
32 Kim H,Sohn A,Yeo I,Yu SJ,Yoon JH,Kim Y.Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma.Clin Chem 2018;64:1230-1238[PMID:29875214 DOI:10.1373/clinchem.2018.289702]
33 Duarte-Salles T,Misra S,Stepien M,Plymoth A,Muller D,Overvad K,Olsen A,Tj?nneland A,Baglietto L,Severi G,Boutron-Ruault MC,Turzanski-Fortner R,Kaaks R,Boeing H,Aleksandrova K,Trichopoulou A,Lagiou P,Bamia C,Pala V,Palli D,Mattiello A,Tumino R,Naccarati A,Bueno-deMesquita HB,Peeters PH,Weiderpass E,Quirós JR,Agudo A,Sánchez-Cantalejo E,Ardanaz E,Gavrila D,Dorronsoro M,Werner M,Hemmingsson O,Ohlsson B,Sj?berg K,Wareham NJ,Khaw KT,Bradbury KE,Gunter MJ,Cross AJ,Riboli E,Jenab M,Hainaut P,Beretta L.Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.Cancer Prev Res(Phila)2016;9:758-765[PMID:27339170 DOI:10.1158/1940-6207.CAPR-15-0434]
34 Ge T,Shen Q,Wang N,Zhang Y,Ge Z,Chu W,Lv X,Zhao F,Zhao W,Fan J,Qin W.Diagnostic values of alpha-fetoprotein,dickkopf-1,and osteopontin for hepatocellular carcinoma.Med Oncol 2015;32(3):59[PMID:25652109 DOI:10.1007/s12032-014-0367-z]
35 Xing H,Zheng YJ,Han J,Zhang H,Li ZL,Lau WY,Shen F,Yang T.Protein induced by vitamin Kabsence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma:Asystematic review with meta-analysis.Hepatobiliary Pancreat Dis Int 2018;17:487-495[PMID:30257796 DOI:10.1016/j.hbpd.2018.09.009]
36 Hu J,Wang N,Yang Y,Ma L,Han R,Zhang W,Yan C,Zheng Y,Wang X.Diagnostic value of alphafetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma.BMCGastroenterol 2018;18:186[PMID:30545306 DOI:10.1186/s12876-018-0908-6]
37 Youssef AA,Issa HA,Omar MZ,Behiry EG,Elfallah AA,Hasaneen A,Darwish M,Ibrahim DB.Serum human endothelial cell-specific molecule-1(endocan)and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality.Clin Exp Gastroenterol 2018;11:431-438[PMID:30538523 DOI:10.2147/CEG.S171339]
38 Li J,Cheng ZJ,Liu Y,Yan ZL,Wang K,Wu D,Wan XY,Xia Y,Lau WY,Wu MC,Shen F.Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.Oncotarget 2015;6:9551-9563[PMID:25871387 DOI:10.18632/oncotarget.3314]
39 Junna Z,Gongde C,Jinying X,Xiu Z.Serum AFU,5'-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis.Open Med(Wars)2017;12:354-358[PMID:29043300 DOI:10.1515/med-2017-0051]
40 Song PP,Xia JF,Inagaki Y,Hasegawa K,Sakamoto Y,Kokudo N,Tang W.Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.World J Gastroenterol 2016;22:262-274[PMID:26755875 DOI:10.3748/wjg.v22.i1.262]
41 Chiba T,Suzuki E,Saito T,Ogasawara S,Ooka Y,Tawada A,Iwama A,Yokosuka O.Biological features and biomarkers in hepatocellular carcinoma.World J Hepatol 2015;7:2020-2028[PMID:26261691 DOI:10.4254/wjh.v7.i16.2020]
42 Shu H,Li W,Shang S,Qin X,Zhang S,Liu Y.Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.Discov Med 2017;23:163-168[PMID:28472609]
43 Wang M,Sanda M,Comunale MA,Herrera H,Swindell C,Kono Y,Singal AG,Marrero J,Block T,Goldman R,Mehta A.Changes in the Glycosylation of Kininogen and the Development of a KininogenBased Algorithm for the Early Detection of HCC.Cancer Epidemiol Biomarkers Prev 2017;26:795-803[PMID:28223431 DOI:10.1158/1055-9965.EPI-16-0974]
44 Guo J,Jing R,Zhong JH,Dong X,Li YX,Liu YK,Huang TR,Zhang CY.Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics.Oncotarget 2017;8:62011-62028[PMID:28977922 DOI:10.18632/oncotarget.18782]
45 Kim H,Park J,Kim Y,Sohn A,Yeo I,Jong Yu S,Yoon JH,Park T,Kim Y.Serum fibronectin distinguishes the early stages of hepatocellular carcinoma.Sci Rep 2017;7:9449[PMID:28842594 DOI:10.1038/s41598-017-09691-3]
46 Chen VL,Le AK,Podlaha O,Estevez J,Li B,Vutien P,Chang ET,Rosenberg-Hasson Y,Pflanz S,Jiang Z,Ge D,Gaggar A,Nguyen MH.Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk:multiplex analysis of serum markers.Sci Rep 2017;7:11169[PMID:28894136 DOI:10.1038/s41598-017-10498-5]
47 Amhimmid Badr S,Waheeb Fahmi M,Mahmoud Nomir M,Mohammad El-Shishtawy M.Calcium channelα2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma.Cancer Biol Med2018;15:52-60[PMID:29545968 DOI:10.20892/j.issn.2095-3941.2017.0167]
48 Wang T,Liu M,Zheng SJ,Bian DD,Zhang JY,Yao J,Zheng QF,Shi AM,Li WH,Li L,Chen Y,Wang JH,Duan ZP,Dong L.Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis ofα-fetoprotein-negative hepatocellular carcinoma.World J Gastroenterol 2017;23:3496-3504[PMID:28596685 DOI:10.3748/wjg.v23.i19.3496]
49 Takaya H,Kawaratani H,Tsuji Y,Nakanishi K,Saikawa S,Sato S,Sawada Y,Kaji K,Okura Y,Shimozato N,Kitade M,Akahane T,Moriya K,Namisaki T,Mitoro A,Matsumoto M,Fukui H,Yoshiji H.von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.United European Gastroenterol J 2018;6:1401-1409[PMID:30386613 DOI:10.1177/2050640618779660]
50 Shen J,Wu H,Peng N,Cai J.An eight cytokine signature identified from peripheral blood serves as a fingerprint for hepatocellular cancer diagnosis.Afr Health Sci 2018;18:260-266[PMID:30602951 DOI:10.4314/ahs.v18i2.9]
51 Tsuchiya N,Sawada Y,Endo I,Saito K,Uemura Y,Nakatsura T.Biomarkers for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol 2015;21:10573-10583[PMID:26457017 DOI:10.3748/wjg.v21.i37.10573]
52 Khattab M,Fouad M,Ahmed E.Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.World J Hepatol 2015;7:2474-2481[PMID:26483869 DOI:10.4254/wjh.v7.i23.2474]
53 Lou J,Zhang L,Lv S,Zhang C,Jiang S.Biomarkers for Hepatocellular Carcinoma.Biomark Cancer2017;9:1-9[PMID:28469485 DOI:10.1177/1179299X16684640]
54 Zhu R,Yang J,Xu L,Dai W,Wang F,Shen M,Zhang Y,Zhang H,Chen K,Cheng P,Wang C,Zheng Y,Li J,Lu J,Zhou Y,Wu D,Guo C.Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma:A Meta-Analysis.Gastroenterol Res Pract 2014;2014:529314[PMID:25165471 DOI:10.1155/2014/529314]
55 Xu H,Dong X,Chen Y,Wang X.Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma.Clin Chem Lab Med 2018;56:479-484[PMID:29252188 DOI:10.1515/cclm-2017-0327]
56 Balkan A,Gulsen MT,Kaya B.Serum microRNA-26,microRNA-122 and microRNA-192 expressions in hepatocellular carcinoma.Acta Medica Mediterranea 2017;33:165[DOI:10.19193/0393-6384_2017_1_025]
57 Long XR,Zhang YJ,Zhang MY,Chen K,Zheng XFS,Wang HY.Identification of an 88-microRNAsignature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases.Aging(Albany NY)2017;9:1565-1584[PMID:28657540 DOI:10.18632/aging.101253]
58 Shi BM,Lu W,Ji K,Wang YF,Xiao S,Wang XY.Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol 2017;23:3713-3720[PMID:28611524DOI:10.3748/wjg.v23.i20.3713]
59 Liu M,Wang L,Zhu H,Rong W,Wu F,Liang S,Xu N,Wu J.A Preoperative Measurement of Serum MicroRNA-125b May Predict the Presence of Microvascular Invasion in Hepatocellular Carcinomas Patients.Transl Oncol 2016;9:167-172[PMID:27267832 DOI:10.1016/j.tranon.2016.03.002]
60 Hu T,Li J,Zhang C,Lv X,Li S,He S,Yan H,Tan Y,Lei M,Wen M,Zuo J.The potential value of microRNA-4463 in the prognosis evaluation in hepatocellular carcinoma.Genes Dis 2017;4:116-122[PMID:30258914 DOI:10.1016/j.gendis.2017.03.003]
61 An Y,Gao S,Zhao WC,Qiu BA,Xia NX,Zhang PJ,Fan ZP.Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma.World J Gastroenterol 2018;24:2596-2604[PMID:29962816 DOI:10.3748/wjg.v24.i24.2596]
62 Jiang L,Cheng Q,Zhang BH,Zhang MZ.Circulating microRNAs as biomarkers in hepatocellular carcinoma screening:a validation set from China.Medicine(Baltimore)2015;94:e603[PMID:25761179DOI:10.1097/MD.0000000000000603]
63 Xue X,Zhao Y,Wang X,Qin L,Hu R.Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma.J Cell Biochem 2019;120:135-142[PMID:30238497 DOI:10.1002/jcb.27165]
64 Liu HN,Wu H,Chen YJ,Tseng YJ,Bilegsaikhan E,Dong L,Shen XZ,Liu TT.Serum microRNAsignatures and metabolomics have high diagnostic value in hepatocellular carcinoma.Oncotarget 2017;8:108810-108824[PMID:29312570 DOI:10.18632/oncotarget.22224]
65 Liao Q,Han P,Huang Y,Wu Z,Chen Q,Li S,Ye J,Wu X.Potential Role of Circulating microRNA-21for Hepatocellular Carcinoma Diagnosis:A Meta-Analysis.PLoS One 2015;10:e0130677[PMID:26114756 DOI:10.1371/journal.pone.0130677]
66 Ding Y,Yan JL,Fang AN,Zhou WF,Huang L.Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection:a meta-analysis based on 24 articles.Oncotarget 2017;8:66402-66413[PMID:29029522 DOI:10.18632/oncotarget.18949]
67 Xu J,Li J,Zheng TH,Bai L,Liu ZJ.MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma.Adv Clin Exp Med 2016;25:971-975[PMID:28028963 DOI:10.17219/acem/36460]
68 Wang Y,Zhang C,Zhang P,Guo G,Jiang T,Zhao X,Jiang J,Huang X,Tong H,Tian Y.Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.Cancer Med 2018;7:1670-1679[PMID:29573235 DOI:10.1002/cam4.1390]
69 Mohamed AA,Ali-Eldin ZA,Elbedewy TA,El-Serafy M,Ali-Eldin FA,AbdelAziz H.MicroRNAs and clinical implications in hepatocellular carcinoma.World J Hepatol 2017;9:1001-1007[PMID:28878865DOI:10.4254/wjh.v9.i23.1001]
70 Motawi TK,Shaker OG,El-Maragh SA,Senousy MA.Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.PLOS One2015;10:e0137706[PMID:26352740 DOI:10.1371/journal.pone.0137706]
71 Amr KS,Elmawgoud Atia HA,Elazeem Elbnhawy RA,Ezzat WM.Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma.Genes Dis 2017;4:215-221[PMID:30258925 DOI:10.1016/j.gendis.2017.10.003]
72 Elemeery MN,Badr AN,Mohamed MA,Ghareeb DA.Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.World J Gastroenterol 2017;23:3864-3875[PMID:28638226 DOI:10.3748/wjg.v23.i21.3864]
73 Fornari F,Ferracin M,Trere D,Milazzo M,Marinelli S,Galassi M,Venerandi L,Pollutri D,Patrizi C,Borghi A,Foschi FG,Stefanini GF,Negrini M,Bolondi L,Gramantieri L.Circulating microRNAs,miR-939,miR-595,miR-519d and miR-494,Identify Cirrhotic Patients with HCC.PLOS One 2015;10:e0141448[PMID:26509672 DOI:10.1371/journal.pone.0141448]
74 Zhuang L,Xu L,Wang P,Meng Z.Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma.PLoS One 2015;10:e0117274[PMID:25642945 DOI:10.1371/journal.pone.0117274]
75 Zhu HT,Hasan AM,Liu RB,Zhang ZC,Zhang X,Wang J,Wang HY,Wang F,Shao JY.Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma.Oncotarget2016;7:45637-45648[PMID:27317768 DOI:10.18632/oncotarget.10082]
76 Klingenberg M,Matsuda A,Diederichs S,Patel T.Non-coding RNA in hepatocellular carcinoma:Mechanisms,biomarkers and therapeutic targets.J Hepatol 2017;67:603-618[PMID:28438689 DOI:10.1016/j.jhep.2017.04.009]
77 Schütte K,Schulz C,Link A,Malfertheiner P.Current biomarkers for hepatocellular carcinoma:Surveillance,diagnosis and prediction of prognosis.World J Hepatol 2015;7:139-149[PMID:25729470DOI:10.4254/wjh.v7.i2.139]
78 Zhang YC,Xu Z,Zhang TF,Wang YL.Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.World J Gastroenterol 2015;21:9853-9862[PMID:26379392 DOI:10.3748/wjg.v21.i34.9853]
79 Loosen SH,Schueller F,Trautwein C,Roy S,Roderburg C.Role of circulating microRNAs in liver diseases.World J Hepatol 2017;9:586-594[PMID:28515844 DOI:10.4254/wjh.v9.i12.586]
80 Yuan W,Sun Y,Liu L,Zhou B,Wang S,Gu D.Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma.Cell Physiol Biochem 2017;44:125-132[PMID:29130980 DOI:10.1159/000484589]
81 Wang K,Guo WX,Li N,Gao CF,Shi J,Tang YF,Shen F,Wu MC,Liu SR,Cheng SQ.Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma.PLoS One 2015;10:e0144934[PMID:26674525 DOI:10.1371/journal.pone.0144934]
82 Tang J,Jiang R,Deng L,Zhang X,Wang K,Sun B.Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.Oncotarget 2015;6:4505-4515[PMID:25714016 DOI:10.18632/oncotarget.2934]
83 Zheng ZK,Pang C,Yang Y,Duan Q,Zhang J,Liu WC.Serum long noncoding RNA urothelial carcinoma-associated 1:A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.J Int Med Res 2018;46:348-356[PMID:28856933 DOI:10.1177/0300060517726441]
84 Xu H,Chen Y,Dong X,Wang X.Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev 2018;27:710-716[PMID:29650788 DOI:10.1158/1055-9965.EPI-17-0770]
85 Chen S,Zhang Y,Wu X,Zhang C,Li G.Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma:An Updated Meta-Analysis.Can J Gastroenterol Hepatol 2018;2018:8410195[PMID:30410873 DOI:10.1155/2018/8410195]
86 Hao QQ,Chen GY,Zhang JH,Sheng JH,Gao Y.Diagnostic value of long noncoding RNAs for hepatocellular carcinoma:A PRISMA-compliant meta-analysis.Medicine(Baltimore)2017;96:e7496[PMID:28700498 DOI:10.1097/MD.0000000000007496]
87 Zheng C,Liu X,Chen L,Xu Z,Shao J.lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma:a systematic review and meta-analysis.Oncotarget 2017;8:59638-59647[PMID:28938667DOI:10.18632/oncotarget.19559]
88 Qin Y,Wu J,Ke Z,Xu J.Expression of plasma lncRNABANCR in hepatocellular carcinomaand its diagnostic and prognostic significance.Int J Clin Med 2017;10:11984-11990
89 Chen Y,Zhou J,Li J,Feng J,Chen Z,Wang X.Plasma metabolomic analysis of human hepatocellular carcinoma:Diagnostic and therapeutic study.Oncotarget 2016;7:47332-47342[PMID:27322079 DOI:10.18632/oncotarget.10119]
90 Kim JU,Shariff MI,Crossey MM,Gomez-Romero M,Holmes E,Cox IJ,Fye HK,Njie R,TaylorRobinson SD.Hepatocellular carcinoma:Review of disease and tumor biomarkers.World J Hepatol 2016;8:471-484[PMID:27057305 DOI:10.4254/wjh.v8.i10.471]
91 Di Poto C,Ferrarini A,Zhao Y,Varghese RS,Tu C,Zuo Y,Wang M,Nezami Ranjbar MR,Luo Y,Zhang C,Desai CS,Shetty K,Tadesse MG,Ressom HW.Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.Cancer Epidemiol Biomarkers Prev2017;26:675-683[PMID:27913395 DOI:10.1158/1055-9965.EPI-16-0366]
92 Saito T,Sugimoto M,Okumoto K,Haga H,Katsumi T,Mizuno K,Nishina T,Sato S,Igarashi K,Maki H,Tomita M,Ueno Y,Soga T.Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C.World J Gastroenterol 2016;22:6224-6234[PMID:27468212 DOI:10.3748/wjg.v22.i27.6224]
93 Fitian AI,Cabrera R.Disease monitoring of hepatocellular carcinoma through metabolomics.World JHepatol 2017;9:1-17[PMID:28105254 DOI:10.4254/wjh.v9.i1.1]
94 Ferrín G,Rodríguez-Perálvarez M,Aguilar-Melero P,Ranchal I,Llamoza C,Linares CI,González-Rubio S,MuntanéJ,Brice?o J,López-Cillero P,Montero-álvarez JL,de la Mata M.Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.PLoS One 2015;10:e0118527[PMID:25789864 DOI:10.1371/journal.pone.0118527]
95 Kimhofer T,Fye H,Taylor-Robinson S,Thursz M,Holmes E.Proteomic and metabonomic biomarkers for hepatocellular carcinoma:a comprehensive review.Br J Cancer 2015;112:1141-1156[PMID:25826224 DOI:10.1038/bjc.2015.38]
96 Guo W,Tan HY,Wang N,Wang X,Feng Y.Deciphering hepatocellular carcinoma through metabolomics:from biomarker discovery to therapy evaluation.Cancer Manag Res 2018;10:715-734[PMID:29692630 DOI:10.2147/CMAR.S156837]
97 Passos-Castilho AM,Lo Turco E,Ferraz ML,Matos C,Silva I,Parise E,Pilau E,Gozzo F,Granato C.Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma,liver cirrhosis,and chronic hepatitis C using MALDI-TOF mass spectrometry:a pilot study.J Gastrointestin Liver Dis 2015;24:43-49[PMID:25822433 DOI:10.15403/jgld.2014.1121.pas]
98 Passos-Castilho AM,Carvalho VM,Cardozo KH,Kikuchi L,Chagas AL,Gomes-Gouvêa MS,Malta F,de Seixas-Santos Nastri AC,Pinho JR,Carrilho FJ,Granato CF.Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.BMC Cancer 2015;15:985[PMID:26680993 DOI:10.1186/s12885-015-1995-1]
99 Margetts J,Ogle LF,Chan SL,Chan AWH,Chan KCA,Jamieson D,Willoughby CE,Mann DA,Wilson CL,Manas DM,Yeo W,Reeves HL.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?Br J Cancer 2018;118:248-257[PMID:29123264 DOI:10.1038/bjc.2017.386]
100 Zheng J,Cai J,Li H,Zeng K,He L,Fu H,Zhang J,Chen L,Yao J,Zhang Y,Yang Y.Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments:a Meta-Analysis and Systematic Review.Cell Physiol Biochem 2017;44:967-981[PMID:29179180 DOI:10.1159/000485396]
101 Goyal H,Hu ZD.Prognostic value of red blood cell distribution width in hepatocellular carcinoma.Ann Transl Med 2017;5:271[PMID:28758097 DOI:10.21037/atm.2017.06.30]
102 Van Hees S,Michielsen P,Vanwolleghem T.Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.World J Gastroenterol 2016;22:8271-8282[PMID:27729734 DOI:10.3748/wjg.v22.i37.8271]
103 Hong Y,Huang J.Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma.World J Hepatol 2015;7:1581-1585[PMID:26085917 DOI:10.4254/wjh.v7.i11.1581]
104 Sun C,Liao W,Deng Z,Li E,Feng Q,Lei J,Yuan R,Zou S,Mao Y,Shao J,Wu L,Zhang C.The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma:A meta-analysis.Medicine(Baltimore)2017;96:e7513[PMID:28723763 DOI:10.1097/MD.0000000000007513]
105 Yu YQ,Wang L,Jin Y,Zhou JL,Geng YH,Jin X,Zhang XX,Yang JJ,Qian CM,Zhou DE,Liu DR,Peng SY,Luo Y,Zheng L,Li JT.Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma.Oncotarget 2016;7:16362-16371[PMID:26918350 DOI:10.18632/oncotarget.7649]
106 Kuo MJ,Chen HH,Chen CL,Fann JC,Chen SL,Chiu SY,Lin YM,Liao CS,Chang HC,Lin YS,Yen AM.Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma:Comparing ultrasonography with two-stage screening.World J Gastroenterol 2016;22:3460-3470[PMID:27022228DOI:10.3748/wjg.v22.i12.3460]
107 Hanna RF,Miloushev VZ,Tang A,Finklestone LA,Brejt SZ,Sandhu RS,Santillan CS,Wolfson T,Gamst A,Sirlin CB.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound,CT,and MRI for detecting hepatocellular carcinoma.Abdom Radiol(NY)2016;41:71-90[PMID:26830614 DOI:10.1007/s00261-015-0592-8]
108 Van Beers BE,Daire JL,Garteiser P.New imaging techniques for liver diseases.J Hepatol 2015;62:690-700[PMID:25457198 DOI:10.1016/j.jhep.2014.10.014]
109 Westwood M,Joore M,Grutters J,Redekop K,Armstrong N,Lee K,Gloy V,Raatz H,Misso K,Severens J,Kleijnen J.Contrast-enhanced ultrasound using SonoVue?(sulphur hexafluoride microbubbles)compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases:a systematic review and cost-effectiveness analysis.Health Technol Assess 2013;17:1-243[PMID:23611316 DOI:10.3310/hta17160]
110 Yao Z,Dong Y,Wu G,Zhang Q,Yang D,Yu JH,Wang WP.Preoperative diagnosis and prediction of hepatocellular carcinoma:Radiomics analysis based on multi-modal ultrasound images.BMC Cancer2018;18:1089[PMID:30419849 DOI:10.1186/s12885-018-5003-4]
111 Ippolito D,Inchingolo R,Grazioli L,Drago SG,Nardella M,Gatti M,Faletti R.Recent advances in noninvasive magnetic resonance imaging assessment of hepatocellular carcinoma.World J Gastroenterol2018;24:2413-2426[PMID:29930464 DOI:10.3748/wjg.v24.i23.2413]
112 Neri E,Bali MA,Ba-Ssalamah A,Boraschi P,Brancatelli G,Alves FC,Grazioli L,Helmberger T,Lee JM,Manfredi R,Martì-BonmatìL,Matos C,Merkle EM,Op De Beeck B,Schima W,Skehan S,Vilgrain V,Zech C,Bartolozzi C.ESGAR consensus statement on liver MR imaging and clinical use of liverspecific contrast agents.Eur Radiol 2016;26:921-931[PMID:26194455 DOI:10.1007/s00330-015-3900-3]
113 Tanabe M,Kanki A,Wolfson T,Costa EA,Mamidipalli A,Ferreira MP,Santillan C,Middleton MS,Gamst AC,Kono Y,Kuo A,Sirlin CB.Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2,3,and 4 Observations Detected at CT and MR Imaging.Radiology 2016;281:129-139[PMID:27115054 DOI:10.1148/radiol.2016152173]
114 Darnell A,Forner A,Rimola J,Reig M,García-Criadoá,Ayuso C,Bruix J.Liver Imaging Reporting and Data System with MR Imaging:Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.Radiology 2015;275:698-707[PMID:25658038 DOI:10.1148/radiol.15141132]
115 Yang JF,Zhao ZH,Zhang Y,Zhao L,Yang LM,Zhang MM,Wang BY,Wang T,Lu BC.Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.World J Gastroenterol 2016;22:3652-3662[PMID:27053857 DOI:10.3748/wjg.v22.i13.3652]
116 Kavanaugh G,Williams J,Morris AS,Nickels ML,Walker R,Koglin N,Stephens AW,Washington MK,Geevarghese SK,Liu Q,Ayers D,Shyr Y,Manning HC.Utility of[18F]FSPG PET to Image Hepatocellular Carcinoma:First Clinical Evaluation in a US Population.Mol Imaging Biol 2016;18:924-934[PMID:27677886 DOI:10.1007/s11307-016-1007-0]
117 Cho Y,Lee DH,Lee YB,Lee M,Yoo JJ,Choi WM,Cho YY,Paeng JC,Kang KW,Chung JK,Yu SJ,Lee JH,Yoon JH,Lee HS,Kim YJ.Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?PLoS One 2014;9:e105679[PMID:25153834DOI:10.1371/journal.pone.0105679]
2 Geneva:World Health Organization.Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection.[PMID:26225396]
3 Geneva:World Health Organization.WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection:Update Version.[PMID:27227200]
4 Burak KW,Sherman M.Hepatocellular carcinoma:Consensus,controversies and future directions.Areport from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.Can JGastroenterol Hepatol 2015;29:178-184[PMID:25965437]
5 Heimbach JK,Kulik LM,Finn RS,Sirlin CB,Abecassis MM,Roberts LR,Zhu AX,Murad MH,Marrero JA.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology 2018;67:358-380[PMID:28130846 DOI:10.1002/hep.29086]
6 Marrero JA,Ahn J,Rajender Reddy K;Americal College of Gastroenterology.ACG clinical guideline:the diagnosis and management of focal liver lesions.Am J Gastroenterol 2014;109:1328-1347;quiz 1348[PMID:25135008 DOI:10.1038/ajg.2014.213]
7 Benson AB,D'Angelica MI,Abbott DE,Abrams TA,Alberts SR,Saenz DA,Are C,Brown DB,Chang DT,Covey AM,Hawkins W,Iyer R,Jacob R,Karachristos A,Kelley RK,Kim R,Palta M,Park JO,Sahai V,Schefter T,Schmidt C,Sicklick JK,Singh G,Sohal D,Stein S,Tian GG,Vauthey JN,Venook AP,Zhu AX,Hoffmann KG,Darlow S.NCCN Guidelines Insights:Hepatobiliary Cancers,Version 1.2017.J Natl Compr Canc Netw 2017;15:563-573[PMID:28476736]
8 Optimal cancer care pathway for people with hepatocellular carcinoma.Available from:www.cancer.org.au/ocp
9 European Association for the Study of the Liver.European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma.J Hepatol 2018;69:182-236[PMID:29628281 DOI:10.1016/j.jhep.2018.03.019]
10 Vogel A,Cervantes A,Chau I,Daniele B,Llovet J,Meyer T,Nault JC,Neumann U,Ricke J,Sangro B,Schirmacher P,Verslype C,Zech CJ,Arnold D,Martinelli E;ESMO Guidelines Committee.Hepatocellular carcinoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol 2018;29:iv238-iv255[PMID:30285213 DOI:10.1093/annonc/mdy308]
11 Kokudo N,Hasegawa K,Akahane M,Igaki H,Izumi N,Ichida T,Uemoto S,Kaneko S,Kawasaki S,Ku Y,Kudo M,Kubo S,Takayama T,Tateishi R,Fukuda T,Matsui O,Matsuyama Y,Murakami T,Arii S,Okazaki M,Makuuchi M.Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma:The Japan Society of Hepatology 2013 update(3rd JSH-HCC Guidelines).Hepatol Res 2015;45[PMID:25625806 DOI:10.1111/hepr.12464]
12 Omata M,Cheng AL,Kokudo N,Kudo M,Lee JM,Jia J,Tateishi R,Han KH,Chawla YK,Shiina S,Jafri W,Payawal DA,Ohki T,Ogasawara S,Chen PJ,Lesmana CRA,Lesmana LA,Gani RA,Obi S,Dokmeci AK,Sarin SK.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update.Hepatol Int 2017;11:317-370[PMID:28620797 DOI:10.1007/s12072-017-9799-9]
13 Claudon M,Dietrich CF,Choi BI,Cosgrove DO,Kudo M,Nols?e CP,Piscaglia F,Wilson SR,Barr RG,Chammas MC,Chaubal NG,Chen MH,Clevert DA,Correas JM,Ding H,Forsberg F,Fowlkes JB,Gibson RN,Goldberg BB,Lassau N,Leen EL,Mattrey RF,Moriyasu F,Solbiati L,Weskott HP,Xu HX.Guidelines and good clinical practice recommendations for contrast enhanced ultrasound(CEUS)in the liver--update 2012:a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB,AIUM,ASUM,FLAUS and ICUS.Ultraschall Med 2013;34:11-29[PMID:23129518 DOI:10.1055/s-0032-1325499]
14 Wang K,Bai Y,Chen S,Huang J,Yuan J,Chen W,Yao P,Miao X,Wang Y,Liang Y,Zhang X,He M,Yang H,Guo H,Wei S.Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.Cancer Med 2018;7:2691-2698[PMID:29696820 DOI:10.1002/cam4.1481]
15 Tayob N,Richardson P,White DL,Yu X,Davila JA,Kanwal F,Feng Z,El-Serag HB.Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.BMC Med Res Methodol 2018;18:1[PMID:29301497 DOI:10.1186/s12874-017-0458-6]
16 Wang M,Devarajan K,Singal AG,Marrero JA,Dai J,Feng Z,Rinaudo JA,Srivastava S,Evans A,Hann HW,Lai Y,Yang H,Block TM,Mehta A.The Doylestown Algorithm:A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.Cancer Prev Res(Phila)2016;9:172-179[PMID:26712941 DOI:10.1158/1940-6207.CAPR-15-0186]
17 Yu R,Ding S,Tan W,Tan S,Tan Z,Xiang S,Zhou Y,Mao Q,Deng G.Performance of Protein Induced by Vitamin K Absence or Antagonist-II(PIVKA-II)for Hepatocellular Carcinoma Screening in Chinese Population.Hepat Mon 2015;15:e28806[PMID:26300931 DOI:10.5812/hepatmon.28806v2]
18 Chen H,Zhang Y,Li S,Li N,Chen Y,Zhang B,Qu C,Ding H,Huang J,Dai M.Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma.Cancer Manag Res 2018;10:1947-1958[PMID:30022853 DOI:10.2147/CMAR.S167036]
19 Fu J,Li Y,Li Z,Li N.Clinical utility of decarboxylation prothrombin combined withα-fetoprotein for diagnosing primary hepatocellular carcinoma.Biosci Rep 2018;38[PMID:29717027 DOI:10.1042/BSR20180044]
20 Qin QF,Weng J,Xu GX,Chen CM,Jia CK.Combination of serum tumor markers dickkopf-1,DCP and AFP for the diagnosis of primary hepatocellular carcinoma.Asian Pac J Trop Med 2017;10:409-413[PMID:28552111 DOI:10.1016/j.apjtm.2017.03.016]
21 Chen J,Wu G,Li Y.Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma:A Meta-Analysis.Dis Markers 2018;2018:8906023[PMID:30402170 DOI:10.1155/2018/8906023]
22 Beale G,Chattopadhyay D,Gray J,Stewart S,Hudson M,Day C,Trerotoli P,Giannelli G,Manas D,Reeves H.AFP,PIVKAII,GP3,SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.BMC Cancer 2008;8:200[PMID:18638391DOI:10.1186/1471-2407-8-200]
23 Yu Y,Song J,Zhang R,Liu Z,Li Q,Shi Y,Chen Y,Chen J.Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma.Oncotarget 2017;8:79722-79730[PMID:29108352 DOI:10.18632/oncotarget.19178]
24 Li B,Li B,Guo T,Sun Z,Li X,Li X,Chen L,Zhao J,Mao Y.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels ofα-fetoprotein,α-fetoprotein-L3,des-γ-carboxy prothrombin,and Golgi protein 73.Oncotarget 2017;8:80521-80530[PMID:29113322 DOI:10.18632/oncotarget.19298]
25 Gao J,Song P.Combination of triple biomarkers AFP,AFP-L3,and PIVAKII for early detection of hepatocellular carcinoma in China:Expectation.Drug Discov Ther 2017;11:168-169[PMID:28757516DOI:10.5582/ddt.2017.01036]
26 Caviglia GP,Abate ML,Petrini E,Gaia S,Rizzetto M,Smedile A.Highly sensitive alpha-fetoprotein,Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.Hepatol Res 2016;46:E130-E135[PMID:26082262 DOI:10.1111/hepr.12544]
27 Best J,Bilgi H,Heider D,Schotten C,Manka P,Bedreli S,Gorray M,Ertle J,van Grunsven LA,Dechêne A.The GALAD scoring algorithm based on AFP,AFP-L3,and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.Z Gastroenterol 2016;54:1296-1305[PMID:27936479DOI:10.1055/S-0042-119529]
28 Berhane S,Toyoda H,Tada T,Kumada T,Kagebayashi C,Satomura S,Schweitzer N,Vogel A,Manns MP,Benckert J,Berg T,Ebker M,Best J,Dechêne A,Gerken G,Schlaak JF,Weinmann A,W?rns MA,Galle P,Yeo W,Mo F,Chan SL,Reeves H,Cox T,Johnson P.Role of the GALAD and BALAD-2Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.Clin Gastroenterol Hepatol 2016;14:875-886.e6[PMID:26775025 DOI:10.1016/j.cgh.2015.12.042]
29 Oeda S,Iwane S,Takasaki M,Furukawa NE,Otsuka T,Eguchi Y,Anzai K.Optimal Follow-up of Patients with Viral Hepatitis Improves the Detection of Early-stage Hepatocellular Carcinoma and the Prognosis of Survival.Intern Med 2016;55:2749-2758[PMID:27725532 DOI:10.2169/internalmedicine.55.6730]
30 Wongjarupong N,Negron-Ocasio GM,Chaiteerakij R,Addissie BD,Mohamed EA,Mara KC,Harmsen WS,Theobald JP,Peters BE,Balsanek JG,Ward MM,Giama NH,Venkatesh SK,Harnois DM,Charlton MR,Yamada H,Algeciras-Schimnich A,Snyder MR,Therneau TM,Roberts LR.Model combining pretransplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.World J Gastroenterol 2018;24:1321-1331[PMID:29599607 DOI:10.3748/wjg.v24.i12.1321]
31 Li B,Li B,Guo T,Sun Z,Li X,Li X,Wang H,Chen W,Chen P,Mao Y.The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma.Biomed Res Int 2017;2017:5358615[PMID:28540298 DOI:10.1155/2017/5358615]
32 Kim H,Sohn A,Yeo I,Yu SJ,Yoon JH,Kim Y.Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma.Clin Chem 2018;64:1230-1238[PMID:29875214 DOI:10.1373/clinchem.2018.289702]
33 Duarte-Salles T,Misra S,Stepien M,Plymoth A,Muller D,Overvad K,Olsen A,Tj?nneland A,Baglietto L,Severi G,Boutron-Ruault MC,Turzanski-Fortner R,Kaaks R,Boeing H,Aleksandrova K,Trichopoulou A,Lagiou P,Bamia C,Pala V,Palli D,Mattiello A,Tumino R,Naccarati A,Bueno-deMesquita HB,Peeters PH,Weiderpass E,Quirós JR,Agudo A,Sánchez-Cantalejo E,Ardanaz E,Gavrila D,Dorronsoro M,Werner M,Hemmingsson O,Ohlsson B,Sj?berg K,Wareham NJ,Khaw KT,Bradbury KE,Gunter MJ,Cross AJ,Riboli E,Jenab M,Hainaut P,Beretta L.Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.Cancer Prev Res(Phila)2016;9:758-765[PMID:27339170 DOI:10.1158/1940-6207.CAPR-15-0434]
34 Ge T,Shen Q,Wang N,Zhang Y,Ge Z,Chu W,Lv X,Zhao F,Zhao W,Fan J,Qin W.Diagnostic values of alpha-fetoprotein,dickkopf-1,and osteopontin for hepatocellular carcinoma.Med Oncol 2015;32(3):59[PMID:25652109 DOI:10.1007/s12032-014-0367-z]
35 Xing H,Zheng YJ,Han J,Zhang H,Li ZL,Lau WY,Shen F,Yang T.Protein induced by vitamin Kabsence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma:Asystematic review with meta-analysis.Hepatobiliary Pancreat Dis Int 2018;17:487-495[PMID:30257796 DOI:10.1016/j.hbpd.2018.09.009]
36 Hu J,Wang N,Yang Y,Ma L,Han R,Zhang W,Yan C,Zheng Y,Wang X.Diagnostic value of alphafetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma.BMCGastroenterol 2018;18:186[PMID:30545306 DOI:10.1186/s12876-018-0908-6]
37 Youssef AA,Issa HA,Omar MZ,Behiry EG,Elfallah AA,Hasaneen A,Darwish M,Ibrahim DB.Serum human endothelial cell-specific molecule-1(endocan)and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality.Clin Exp Gastroenterol 2018;11:431-438[PMID:30538523 DOI:10.2147/CEG.S171339]
38 Li J,Cheng ZJ,Liu Y,Yan ZL,Wang K,Wu D,Wan XY,Xia Y,Lau WY,Wu MC,Shen F.Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.Oncotarget 2015;6:9551-9563[PMID:25871387 DOI:10.18632/oncotarget.3314]
39 Junna Z,Gongde C,Jinying X,Xiu Z.Serum AFU,5'-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis.Open Med(Wars)2017;12:354-358[PMID:29043300 DOI:10.1515/med-2017-0051]
40 Song PP,Xia JF,Inagaki Y,Hasegawa K,Sakamoto Y,Kokudo N,Tang W.Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.World J Gastroenterol 2016;22:262-274[PMID:26755875 DOI:10.3748/wjg.v22.i1.262]
41 Chiba T,Suzuki E,Saito T,Ogasawara S,Ooka Y,Tawada A,Iwama A,Yokosuka O.Biological features and biomarkers in hepatocellular carcinoma.World J Hepatol 2015;7:2020-2028[PMID:26261691 DOI:10.4254/wjh.v7.i16.2020]
42 Shu H,Li W,Shang S,Qin X,Zhang S,Liu Y.Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.Discov Med 2017;23:163-168[PMID:28472609]
43 Wang M,Sanda M,Comunale MA,Herrera H,Swindell C,Kono Y,Singal AG,Marrero J,Block T,Goldman R,Mehta A.Changes in the Glycosylation of Kininogen and the Development of a KininogenBased Algorithm for the Early Detection of HCC.Cancer Epidemiol Biomarkers Prev 2017;26:795-803[PMID:28223431 DOI:10.1158/1055-9965.EPI-16-0974]
44 Guo J,Jing R,Zhong JH,Dong X,Li YX,Liu YK,Huang TR,Zhang CY.Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics.Oncotarget 2017;8:62011-62028[PMID:28977922 DOI:10.18632/oncotarget.18782]
45 Kim H,Park J,Kim Y,Sohn A,Yeo I,Jong Yu S,Yoon JH,Park T,Kim Y.Serum fibronectin distinguishes the early stages of hepatocellular carcinoma.Sci Rep 2017;7:9449[PMID:28842594 DOI:10.1038/s41598-017-09691-3]
46 Chen VL,Le AK,Podlaha O,Estevez J,Li B,Vutien P,Chang ET,Rosenberg-Hasson Y,Pflanz S,Jiang Z,Ge D,Gaggar A,Nguyen MH.Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk:multiplex analysis of serum markers.Sci Rep 2017;7:11169[PMID:28894136 DOI:10.1038/s41598-017-10498-5]
47 Amhimmid Badr S,Waheeb Fahmi M,Mahmoud Nomir M,Mohammad El-Shishtawy M.Calcium channelα2δ1 subunit as a novel biomarker for diagnosis of hepatocellular carcinoma.Cancer Biol Med2018;15:52-60[PMID:29545968 DOI:10.20892/j.issn.2095-3941.2017.0167]
48 Wang T,Liu M,Zheng SJ,Bian DD,Zhang JY,Yao J,Zheng QF,Shi AM,Li WH,Li L,Chen Y,Wang JH,Duan ZP,Dong L.Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis ofα-fetoprotein-negative hepatocellular carcinoma.World J Gastroenterol 2017;23:3496-3504[PMID:28596685 DOI:10.3748/wjg.v23.i19.3496]
49 Takaya H,Kawaratani H,Tsuji Y,Nakanishi K,Saikawa S,Sato S,Sawada Y,Kaji K,Okura Y,Shimozato N,Kitade M,Akahane T,Moriya K,Namisaki T,Mitoro A,Matsumoto M,Fukui H,Yoshiji H.von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.United European Gastroenterol J 2018;6:1401-1409[PMID:30386613 DOI:10.1177/2050640618779660]
50 Shen J,Wu H,Peng N,Cai J.An eight cytokine signature identified from peripheral blood serves as a fingerprint for hepatocellular cancer diagnosis.Afr Health Sci 2018;18:260-266[PMID:30602951 DOI:10.4314/ahs.v18i2.9]
51 Tsuchiya N,Sawada Y,Endo I,Saito K,Uemura Y,Nakatsura T.Biomarkers for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol 2015;21:10573-10583[PMID:26457017 DOI:10.3748/wjg.v21.i37.10573]
52 Khattab M,Fouad M,Ahmed E.Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.World J Hepatol 2015;7:2474-2481[PMID:26483869 DOI:10.4254/wjh.v7.i23.2474]
53 Lou J,Zhang L,Lv S,Zhang C,Jiang S.Biomarkers for Hepatocellular Carcinoma.Biomark Cancer2017;9:1-9[PMID:28469485 DOI:10.1177/1179299X16684640]
54 Zhu R,Yang J,Xu L,Dai W,Wang F,Shen M,Zhang Y,Zhang H,Chen K,Cheng P,Wang C,Zheng Y,Li J,Lu J,Zhou Y,Wu D,Guo C.Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma:A Meta-Analysis.Gastroenterol Res Pract 2014;2014:529314[PMID:25165471 DOI:10.1155/2014/529314]
55 Xu H,Dong X,Chen Y,Wang X.Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma.Clin Chem Lab Med 2018;56:479-484[PMID:29252188 DOI:10.1515/cclm-2017-0327]
56 Balkan A,Gulsen MT,Kaya B.Serum microRNA-26,microRNA-122 and microRNA-192 expressions in hepatocellular carcinoma.Acta Medica Mediterranea 2017;33:165[DOI:10.19193/0393-6384_2017_1_025]
57 Long XR,Zhang YJ,Zhang MY,Chen K,Zheng XFS,Wang HY.Identification of an 88-microRNAsignature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases.Aging(Albany NY)2017;9:1565-1584[PMID:28657540 DOI:10.18632/aging.101253]
58 Shi BM,Lu W,Ji K,Wang YF,Xiao S,Wang XY.Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol 2017;23:3713-3720[PMID:28611524DOI:10.3748/wjg.v23.i20.3713]
59 Liu M,Wang L,Zhu H,Rong W,Wu F,Liang S,Xu N,Wu J.A Preoperative Measurement of Serum MicroRNA-125b May Predict the Presence of Microvascular Invasion in Hepatocellular Carcinomas Patients.Transl Oncol 2016;9:167-172[PMID:27267832 DOI:10.1016/j.tranon.2016.03.002]
60 Hu T,Li J,Zhang C,Lv X,Li S,He S,Yan H,Tan Y,Lei M,Wen M,Zuo J.The potential value of microRNA-4463 in the prognosis evaluation in hepatocellular carcinoma.Genes Dis 2017;4:116-122[PMID:30258914 DOI:10.1016/j.gendis.2017.03.003]
61 An Y,Gao S,Zhao WC,Qiu BA,Xia NX,Zhang PJ,Fan ZP.Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma.World J Gastroenterol 2018;24:2596-2604[PMID:29962816 DOI:10.3748/wjg.v24.i24.2596]
62 Jiang L,Cheng Q,Zhang BH,Zhang MZ.Circulating microRNAs as biomarkers in hepatocellular carcinoma screening:a validation set from China.Medicine(Baltimore)2015;94:e603[PMID:25761179DOI:10.1097/MD.0000000000000603]
63 Xue X,Zhao Y,Wang X,Qin L,Hu R.Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma.J Cell Biochem 2019;120:135-142[PMID:30238497 DOI:10.1002/jcb.27165]
64 Liu HN,Wu H,Chen YJ,Tseng YJ,Bilegsaikhan E,Dong L,Shen XZ,Liu TT.Serum microRNAsignatures and metabolomics have high diagnostic value in hepatocellular carcinoma.Oncotarget 2017;8:108810-108824[PMID:29312570 DOI:10.18632/oncotarget.22224]
65 Liao Q,Han P,Huang Y,Wu Z,Chen Q,Li S,Ye J,Wu X.Potential Role of Circulating microRNA-21for Hepatocellular Carcinoma Diagnosis:A Meta-Analysis.PLoS One 2015;10:e0130677[PMID:26114756 DOI:10.1371/journal.pone.0130677]
66 Ding Y,Yan JL,Fang AN,Zhou WF,Huang L.Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection:a meta-analysis based on 24 articles.Oncotarget 2017;8:66402-66413[PMID:29029522 DOI:10.18632/oncotarget.18949]
67 Xu J,Li J,Zheng TH,Bai L,Liu ZJ.MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma.Adv Clin Exp Med 2016;25:971-975[PMID:28028963 DOI:10.17219/acem/36460]
68 Wang Y,Zhang C,Zhang P,Guo G,Jiang T,Zhao X,Jiang J,Huang X,Tong H,Tian Y.Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.Cancer Med 2018;7:1670-1679[PMID:29573235 DOI:10.1002/cam4.1390]
69 Mohamed AA,Ali-Eldin ZA,Elbedewy TA,El-Serafy M,Ali-Eldin FA,AbdelAziz H.MicroRNAs and clinical implications in hepatocellular carcinoma.World J Hepatol 2017;9:1001-1007[PMID:28878865DOI:10.4254/wjh.v9.i23.1001]
70 Motawi TK,Shaker OG,El-Maragh SA,Senousy MA.Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.PLOS One2015;10:e0137706[PMID:26352740 DOI:10.1371/journal.pone.0137706]
71 Amr KS,Elmawgoud Atia HA,Elazeem Elbnhawy RA,Ezzat WM.Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma.Genes Dis 2017;4:215-221[PMID:30258925 DOI:10.1016/j.gendis.2017.10.003]
72 Elemeery MN,Badr AN,Mohamed MA,Ghareeb DA.Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.World J Gastroenterol 2017;23:3864-3875[PMID:28638226 DOI:10.3748/wjg.v23.i21.3864]
73 Fornari F,Ferracin M,Trere D,Milazzo M,Marinelli S,Galassi M,Venerandi L,Pollutri D,Patrizi C,Borghi A,Foschi FG,Stefanini GF,Negrini M,Bolondi L,Gramantieri L.Circulating microRNAs,miR-939,miR-595,miR-519d and miR-494,Identify Cirrhotic Patients with HCC.PLOS One 2015;10:e0141448[PMID:26509672 DOI:10.1371/journal.pone.0141448]
74 Zhuang L,Xu L,Wang P,Meng Z.Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma.PLoS One 2015;10:e0117274[PMID:25642945 DOI:10.1371/journal.pone.0117274]
75 Zhu HT,Hasan AM,Liu RB,Zhang ZC,Zhang X,Wang J,Wang HY,Wang F,Shao JY.Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma.Oncotarget2016;7:45637-45648[PMID:27317768 DOI:10.18632/oncotarget.10082]
76 Klingenberg M,Matsuda A,Diederichs S,Patel T.Non-coding RNA in hepatocellular carcinoma:Mechanisms,biomarkers and therapeutic targets.J Hepatol 2017;67:603-618[PMID:28438689 DOI:10.1016/j.jhep.2017.04.009]
77 Schütte K,Schulz C,Link A,Malfertheiner P.Current biomarkers for hepatocellular carcinoma:Surveillance,diagnosis and prediction of prognosis.World J Hepatol 2015;7:139-149[PMID:25729470DOI:10.4254/wjh.v7.i2.139]
78 Zhang YC,Xu Z,Zhang TF,Wang YL.Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.World J Gastroenterol 2015;21:9853-9862[PMID:26379392 DOI:10.3748/wjg.v21.i34.9853]
79 Loosen SH,Schueller F,Trautwein C,Roy S,Roderburg C.Role of circulating microRNAs in liver diseases.World J Hepatol 2017;9:586-594[PMID:28515844 DOI:10.4254/wjh.v9.i12.586]
80 Yuan W,Sun Y,Liu L,Zhou B,Wang S,Gu D.Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma.Cell Physiol Biochem 2017;44:125-132[PMID:29130980 DOI:10.1159/000484589]
81 Wang K,Guo WX,Li N,Gao CF,Shi J,Tang YF,Shen F,Wu MC,Liu SR,Cheng SQ.Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma.PLoS One 2015;10:e0144934[PMID:26674525 DOI:10.1371/journal.pone.0144934]
82 Tang J,Jiang R,Deng L,Zhang X,Wang K,Sun B.Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma.Oncotarget 2015;6:4505-4515[PMID:25714016 DOI:10.18632/oncotarget.2934]
83 Zheng ZK,Pang C,Yang Y,Duan Q,Zhang J,Liu WC.Serum long noncoding RNA urothelial carcinoma-associated 1:A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.J Int Med Res 2018;46:348-356[PMID:28856933 DOI:10.1177/0300060517726441]
84 Xu H,Chen Y,Dong X,Wang X.Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev 2018;27:710-716[PMID:29650788 DOI:10.1158/1055-9965.EPI-17-0770]
85 Chen S,Zhang Y,Wu X,Zhang C,Li G.Diagnostic Value of lncRNAs as Biomarker in Hepatocellular Carcinoma:An Updated Meta-Analysis.Can J Gastroenterol Hepatol 2018;2018:8410195[PMID:30410873 DOI:10.1155/2018/8410195]
86 Hao QQ,Chen GY,Zhang JH,Sheng JH,Gao Y.Diagnostic value of long noncoding RNAs for hepatocellular carcinoma:A PRISMA-compliant meta-analysis.Medicine(Baltimore)2017;96:e7496[PMID:28700498 DOI:10.1097/MD.0000000000007496]
87 Zheng C,Liu X,Chen L,Xu Z,Shao J.lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma:a systematic review and meta-analysis.Oncotarget 2017;8:59638-59647[PMID:28938667DOI:10.18632/oncotarget.19559]
88 Qin Y,Wu J,Ke Z,Xu J.Expression of plasma lncRNABANCR in hepatocellular carcinomaand its diagnostic and prognostic significance.Int J Clin Med 2017;10:11984-11990
89 Chen Y,Zhou J,Li J,Feng J,Chen Z,Wang X.Plasma metabolomic analysis of human hepatocellular carcinoma:Diagnostic and therapeutic study.Oncotarget 2016;7:47332-47342[PMID:27322079 DOI:10.18632/oncotarget.10119]
90 Kim JU,Shariff MI,Crossey MM,Gomez-Romero M,Holmes E,Cox IJ,Fye HK,Njie R,TaylorRobinson SD.Hepatocellular carcinoma:Review of disease and tumor biomarkers.World J Hepatol 2016;8:471-484[PMID:27057305 DOI:10.4254/wjh.v8.i10.471]
91 Di Poto C,Ferrarini A,Zhao Y,Varghese RS,Tu C,Zuo Y,Wang M,Nezami Ranjbar MR,Luo Y,Zhang C,Desai CS,Shetty K,Tadesse MG,Ressom HW.Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.Cancer Epidemiol Biomarkers Prev2017;26:675-683[PMID:27913395 DOI:10.1158/1055-9965.EPI-16-0366]
92 Saito T,Sugimoto M,Okumoto K,Haga H,Katsumi T,Mizuno K,Nishina T,Sato S,Igarashi K,Maki H,Tomita M,Ueno Y,Soga T.Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C.World J Gastroenterol 2016;22:6224-6234[PMID:27468212 DOI:10.3748/wjg.v22.i27.6224]
93 Fitian AI,Cabrera R.Disease monitoring of hepatocellular carcinoma through metabolomics.World JHepatol 2017;9:1-17[PMID:28105254 DOI:10.4254/wjh.v9.i1.1]
94 Ferrín G,Rodríguez-Perálvarez M,Aguilar-Melero P,Ranchal I,Llamoza C,Linares CI,González-Rubio S,MuntanéJ,Brice?o J,López-Cillero P,Montero-álvarez JL,de la Mata M.Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.PLoS One 2015;10:e0118527[PMID:25789864 DOI:10.1371/journal.pone.0118527]
95 Kimhofer T,Fye H,Taylor-Robinson S,Thursz M,Holmes E.Proteomic and metabonomic biomarkers for hepatocellular carcinoma:a comprehensive review.Br J Cancer 2015;112:1141-1156[PMID:25826224 DOI:10.1038/bjc.2015.38]
96 Guo W,Tan HY,Wang N,Wang X,Feng Y.Deciphering hepatocellular carcinoma through metabolomics:from biomarker discovery to therapy evaluation.Cancer Manag Res 2018;10:715-734[PMID:29692630 DOI:10.2147/CMAR.S156837]
97 Passos-Castilho AM,Lo Turco E,Ferraz ML,Matos C,Silva I,Parise E,Pilau E,Gozzo F,Granato C.Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma,liver cirrhosis,and chronic hepatitis C using MALDI-TOF mass spectrometry:a pilot study.J Gastrointestin Liver Dis 2015;24:43-49[PMID:25822433 DOI:10.15403/jgld.2014.1121.pas]
98 Passos-Castilho AM,Carvalho VM,Cardozo KH,Kikuchi L,Chagas AL,Gomes-Gouvêa MS,Malta F,de Seixas-Santos Nastri AC,Pinho JR,Carrilho FJ,Granato CF.Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.BMC Cancer 2015;15:985[PMID:26680993 DOI:10.1186/s12885-015-1995-1]
99 Margetts J,Ogle LF,Chan SL,Chan AWH,Chan KCA,Jamieson D,Willoughby CE,Mann DA,Wilson CL,Manas DM,Yeo W,Reeves HL.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?Br J Cancer 2018;118:248-257[PMID:29123264 DOI:10.1038/bjc.2017.386]
100 Zheng J,Cai J,Li H,Zeng K,He L,Fu H,Zhang J,Chen L,Yao J,Zhang Y,Yang Y.Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments:a Meta-Analysis and Systematic Review.Cell Physiol Biochem 2017;44:967-981[PMID:29179180 DOI:10.1159/000485396]
101 Goyal H,Hu ZD.Prognostic value of red blood cell distribution width in hepatocellular carcinoma.Ann Transl Med 2017;5:271[PMID:28758097 DOI:10.21037/atm.2017.06.30]
102 Van Hees S,Michielsen P,Vanwolleghem T.Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.World J Gastroenterol 2016;22:8271-8282[PMID:27729734 DOI:10.3748/wjg.v22.i37.8271]
103 Hong Y,Huang J.Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma.World J Hepatol 2015;7:1581-1585[PMID:26085917 DOI:10.4254/wjh.v7.i11.1581]
104 Sun C,Liao W,Deng Z,Li E,Feng Q,Lei J,Yuan R,Zou S,Mao Y,Shao J,Wu L,Zhang C.The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma:A meta-analysis.Medicine(Baltimore)2017;96:e7513[PMID:28723763 DOI:10.1097/MD.0000000000007513]
105 Yu YQ,Wang L,Jin Y,Zhou JL,Geng YH,Jin X,Zhang XX,Yang JJ,Qian CM,Zhou DE,Liu DR,Peng SY,Luo Y,Zheng L,Li JT.Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma.Oncotarget 2016;7:16362-16371[PMID:26918350 DOI:10.18632/oncotarget.7649]
106 Kuo MJ,Chen HH,Chen CL,Fann JC,Chen SL,Chiu SY,Lin YM,Liao CS,Chang HC,Lin YS,Yen AM.Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma:Comparing ultrasonography with two-stage screening.World J Gastroenterol 2016;22:3460-3470[PMID:27022228DOI:10.3748/wjg.v22.i12.3460]
107 Hanna RF,Miloushev VZ,Tang A,Finklestone LA,Brejt SZ,Sandhu RS,Santillan CS,Wolfson T,Gamst A,Sirlin CB.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound,CT,and MRI for detecting hepatocellular carcinoma.Abdom Radiol(NY)2016;41:71-90[PMID:26830614 DOI:10.1007/s00261-015-0592-8]
108 Van Beers BE,Daire JL,Garteiser P.New imaging techniques for liver diseases.J Hepatol 2015;62:690-700[PMID:25457198 DOI:10.1016/j.jhep.2014.10.014]
109 Westwood M,Joore M,Grutters J,Redekop K,Armstrong N,Lee K,Gloy V,Raatz H,Misso K,Severens J,Kleijnen J.Contrast-enhanced ultrasound using SonoVue?(sulphur hexafluoride microbubbles)compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases:a systematic review and cost-effectiveness analysis.Health Technol Assess 2013;17:1-243[PMID:23611316 DOI:10.3310/hta17160]
110 Yao Z,Dong Y,Wu G,Zhang Q,Yang D,Yu JH,Wang WP.Preoperative diagnosis and prediction of hepatocellular carcinoma:Radiomics analysis based on multi-modal ultrasound images.BMC Cancer2018;18:1089[PMID:30419849 DOI:10.1186/s12885-018-5003-4]
111 Ippolito D,Inchingolo R,Grazioli L,Drago SG,Nardella M,Gatti M,Faletti R.Recent advances in noninvasive magnetic resonance imaging assessment of hepatocellular carcinoma.World J Gastroenterol2018;24:2413-2426[PMID:29930464 DOI:10.3748/wjg.v24.i23.2413]
112 Neri E,Bali MA,Ba-Ssalamah A,Boraschi P,Brancatelli G,Alves FC,Grazioli L,Helmberger T,Lee JM,Manfredi R,Martì-BonmatìL,Matos C,Merkle EM,Op De Beeck B,Schima W,Skehan S,Vilgrain V,Zech C,Bartolozzi C.ESGAR consensus statement on liver MR imaging and clinical use of liverspecific contrast agents.Eur Radiol 2016;26:921-931[PMID:26194455 DOI:10.1007/s00330-015-3900-3]
113 Tanabe M,Kanki A,Wolfson T,Costa EA,Mamidipalli A,Ferreira MP,Santillan C,Middleton MS,Gamst AC,Kono Y,Kuo A,Sirlin CB.Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2,3,and 4 Observations Detected at CT and MR Imaging.Radiology 2016;281:129-139[PMID:27115054 DOI:10.1148/radiol.2016152173]
114 Darnell A,Forner A,Rimola J,Reig M,García-Criadoá,Ayuso C,Bruix J.Liver Imaging Reporting and Data System with MR Imaging:Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.Radiology 2015;275:698-707[PMID:25658038 DOI:10.1148/radiol.15141132]
115 Yang JF,Zhao ZH,Zhang Y,Zhao L,Yang LM,Zhang MM,Wang BY,Wang T,Lu BC.Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.World J Gastroenterol 2016;22:3652-3662[PMID:27053857 DOI:10.3748/wjg.v22.i13.3652]
116 Kavanaugh G,Williams J,Morris AS,Nickels ML,Walker R,Koglin N,Stephens AW,Washington MK,Geevarghese SK,Liu Q,Ayers D,Shyr Y,Manning HC.Utility of[18F]FSPG PET to Image Hepatocellular Carcinoma:First Clinical Evaluation in a US Population.Mol Imaging Biol 2016;18:924-934[PMID:27677886 DOI:10.1007/s11307-016-1007-0]
117 Cho Y,Lee DH,Lee YB,Lee M,Yoo JJ,Choi WM,Cho YY,Paeng JC,Kang KW,Chung JK,Yu SJ,Lee JH,Yoon JH,Lee HS,Kim YJ.Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?PLoS One 2014;9:e105679[PMID:25153834DOI:10.1371/journal.pone.0105679]
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |